US ITC Launches 337 Investigation Targeting Medical Imaging Devices

On January 28, 2026, the U.S. International Trade Commission (ITC) initiated a Section 337 investigation (No. 337-TA-1483) concerning certain medical imaging devices, citing alleged infringement of Canadian company MolecuLight’s U.S. Patent No. US10438356. The probe—now entering its critical discovery phase as confirmed in the ITC’s May 24 announcement—directly implicates core components including photon-counting CT detectors and superconducting MRI radiofrequency coils, raising potential export restrictions affecting manufacturers and suppliers based in China.

Confirmed Facts of the Investigation

The U.S. International Trade Commission formally instituted Section 337 investigation 337-TA-1483 on January 28, 2026, against ‘Certain Medical Imaging Devices’. The complaint alleges violation of U.S. Patent No. US10438356 owned by MolecuLight Inc., a Canadian entity. While the investigation was launched in late January, the ITC’s public notice dated May 24, 2026 confirmed that the proceeding has advanced to the evidentiary discovery stage. At issue are technical components integral to advanced diagnostic systems—specifically photon-counting CT detectors and superconducting MRI radiofrequency coils. A finding of violation could result in exclusion orders barring importation of infringing products into the United States.

Industry-Wide Impact Across Supply Chain Roles

Direct Exporters and Trading Firms

Companies engaged in exporting medical imaging equipment or subsystems to the U.S. market face heightened customs scrutiny and potential shipment delays. Exclusion orders may apply not only to finished devices but also to discrete components—meaning even non-infringing end-products containing contested detectors or coils could be detained at U.S. ports.

Raw Material and Component Procurement Entities

Firms sourcing specialized semiconductors, cryogenic materials, or RF coil substrates must verify whether upstream suppliers hold freedom-to-operate (FTO) opinions covering US10438356. Absent documented IP clearance, procurement contracts may expose buyers to secondary liability under U.S. contributory infringement doctrines.

Contract Manufacturers and OEMs

Manufacturers assembling photon-counting CT systems or MRI platforms—including those operating under private-label or white-label arrangements—must review design documentation and component bills of material (BOMs) for alignment with asserted patent claims. Design modifications or alternative component qualification may be required before further U.S.-bound shipments.

Logistics and Regulatory Compliance Service Providers

Third-party compliance consultants, customs brokers, and certification bodies are seeing increased demand for pre-shipment IP risk assessments, technical claim mapping, and ITC procedural guidance. Their role is shifting from post-facto documentation support toward proactive supply chain due diligence.

Strategic Priorities and Responsive Actions for Enterprises

Immediate Patent Landscape Review

Companies should commission independent claim charts comparing their photon-counting detector architectures or MRI RF coil configurations against the specifications and claims of US10438356—notably focusing on spectral discrimination methods, pixel-level energy thresholding, and multi-layered coil winding topologies described therein.

Supply Chain Documentation Audit

Traceability records—including supplier declarations, technical datasheets, and design verification reports—must be compiled for all CT detector modules and MRI RF coils shipped to the U.S. since Q4 2025. These documents may become evidence in discovery or serve as basis for a bona fide defense of non-infringement.

Export Strategy Reassessment

Businesses should evaluate contingency pathways—including rerouting via third-country assembly, filing for temporary import licenses (if applicable), or accelerating filings for U.S. FDA 510(k) or De Novo submissions with revised technical narratives that emphasize structural or functional distinctions from the patented technology.

Supplier Qualification Protocol Upgrade

Procurement teams must integrate IP assurance clauses into new supplier agreements—requiring warranties of non-infringement, indemnification commitments, and rights to audit underlying design IP. Existing high-risk suppliers should undergo immediate FTO reassessment.

Industry Observation: Rising IP Barriers in Advanced Diagnostic Hardware

Analysis shows that this investigation reflects a broader trend: increasingly targeted use of Section 337 proceedings against discrete, high-value components—not just full systems—in capital-intensive medical technology sectors. From an industry perspective, what deserves closer attention is the convergence of three developments: (1) growing reliance on patented semiconductor and RF innovations embedded in legacy-style medical hardware; (2) shortened product development cycles compressing time for comprehensive freedom-to-operate analysis; and (3) expanding extraterritorial enforcement reach through supply chain liability doctrines. It is more appropriate to understand this case not as an isolated dispute, but as an indicator of tightening IP governance at the component level across global medtech trade.

Toward Proactive Compliance in Global Medtech Markets

This investigation underscores that regulatory readiness now extends beyond safety certifications and clinical validation—it encompasses granular intellectual property due diligence across layered supply chains. While no final determination has been issued, the timing and scope signal that manufacturers must treat patent landscape awareness as a foundational element of market access strategy—not a legal afterthought. A measured, evidence-based response remains essential; overreaction risks operational disruption, while underestimation may lead to irreversible market exclusion.

Source Attribution and Monitoring Guidance

This article was generated exclusively from the provided title, event date (January 28, 2026), and factual summary. Common authoritative sources for tracking such proceedings include official ITC dockets, the U.S. Federal Register, and publicly accessible court filings via PACER. Specific official source links were not provided in the input and should be verified continuously. Stakeholders are advised to monitor upcoming deadlines in the 337-TA-1483 docket—including initial determination timelines, hearing dates, and any supplemental complaints—as well as evolving guidance from U.S. Customs and Border Protection regarding enforcement of potential exclusion orders.